Delpacibart etedesiran
Alternative Names: AOC-1001Latest Information Update: 17 Jun 2024
At a glance
- Originator Avidity Biosciences
- Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Small interfering RNA
- Mechanism of Action Myotonin protein kinase expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Myotonic dystrophy
Most Recent Events
- 30 May 2024 Phase-III clinical trials in Myotonic dystrophy in USA (IV) (NCT06411288)
- 09 May 2024 Avidity Biosciences plans a phase III HARBOR™ trial of AOC 1001 for adults living with myotonic dystrophy type 1 (DM1) in the mid of 2024.
- 08 May 2024 AOC 1001 receives Breakthrough Therapy status for Myotonic dystrophy in USA